Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Exosomes: Double-edged Weapon in Cancer Therapy

Author(s): Heba A. Eassa*

Volume 29, Issue 30, 2023

Published on: 19 October, 2023

Page: [2366 - 2368] Pages: 3

DOI: 10.2174/0113816128272352231013074525

Price: $65

conference banner
« Previous Next »
[1]
Volpe JJ. Commentary: Exosomes: Realization of the great therapeutic potential of stem cells. J Neonatal Perinatal Med 2020; 13(3): 287-91.
[2]
Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B. Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: Direct contact, soluble factors, and extracellular vesicles. Front Oncol 2020; 10: 1422.
[3]
Shi Z-Y, Yang X-X, Malichewe C, Li Y-S, Guo X-L. Exosomal microRNAs-mediated intercellular communication and exosome-based cancer treatment. Int J Biol Macromol 2020; 158: 530-41.
[http://dx.doi.org/10.1016/j.ijbiomac.2020.04.228]
[4]
Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: Diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol 2012; 13(5): 328-35.
[http://dx.doi.org/10.1038/nrm3335]
[5]
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020; 367(6478): eaau6977.
[http://dx.doi.org/10.1126/science.aau6977]
[6]
Kok VC, Yu CC. Cancer-derived exosomes. Int J Nanomedicine 2020; 15: 8019-36.
[http://dx.doi.org/10.2147/IJN.S272378] [PMID: 33116515]
[7]
Bang C, Thum T. Exosomes: New players in cell-cell communication. Int J Biochem Cell Biol 2012; 44(11): 2060-4.
[8]
Jiang J, Mei J, Ma Y, et al. Tumor hijacks macrophages and microbiota through extracellular vesicles. Exploration 2022; 2(1): 20210144.
[http://dx.doi.org/10.1002/EXP.20210144]
[9]
Zebrowska A, Widlak P, Whiteside T, Pietrowska M. Signaling of tumor-derived sEV impacts melanoma progression. Int J Mol Sci 2020; 21(14): 5066.
[http://dx.doi.org/10.3390/ijms21145066]
[10]
Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 2018; 560(7718): 382-6.
[http://dx.doi.org/10.1038/s41586-018-0392-8]
[11]
Olejarz W, Dominiak A, Żołnierzak A, Kubiak-Tomaszewska G, Lorenc T. Tumor-derived exosomes in immunosuppression and immunotherapy. J Immunol Res 2020; 2020: 6272498.
[12]
Zhang C, Ji Q, Yang Y, Li Q, Wang Z. Exosome: Function and role in cancer metastasis and drug resistance. Technol Cancer Res Treat 2018; 17: 1533033818763450.
[13]
Damo M, Wilson DS, Simeoni E, Hubbell JA. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep 2015; 5: 17622.
[14]
Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3(1): 9.
[15]
Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial. J Transl Med 2005; 3(1): 10.
[16]
Sasabe E, Tomomura A, Liu H, Sento S, Kitamura N, Yamamoto T. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis. Cancer Sci 2022; 113(2): 609-21.
[17]
Srivastava A, Rathore S, Munshi A, Ramesh R. Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment. Semin Cancer Biol 2022; 86(Pt 1): 80-100.
[http://dx.doi.org/10.1016/j.semcancer.2022.02.020]
[18]
Wang J, Li M, Jin L, et al. Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma in vitro and in vivo. Drug Deliv 2022; 29(1): 3291-303.
[http://dx.doi.org/10.1080/10717544.2022.2141921]
[19]
Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 2016; 12(3): 655-64.
[http://dx.doi.org/10.1016/j.nano.2015.10.012]
[20]
Zhao X, Wu D, Ma X, Wang J, Hou W, Zhang W. Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake. Biomed Pharmacother 2020; 128: 110237.
[http://dx.doi.org/10.1016/j.biopha.2020.110237]
[21]
Usman WM, Pham TC, Kwok YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun 2018; 9(1): 2359.
[http://dx.doi.org/10.1038/s41467-018-04791-8]
[22]
Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 2017; 546(7659): 498-503.
[http://dx.doi.org/10.1038/nature22341]
[23]
Smolarz B, Durczyński A, Romanowicz H, Szyłło K, Hogendorf P. miRNAs in cancer (review of literature). Int J Mol Sci 2022; 23(5): 2805.
[24]
Ding Y, Cao F, Sun H, et al. Exosomes derived from human umbilical cord mesenchymal stromal cells deliver exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression. Cancer Lett 2019; 442: 351-61.
[http://dx.doi.org/10.1016/j.canlet.2018.10.039]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy